All type of patients: 1 trials - Martin (motesanib)
| motesanib + paclitaxel vs paclitaxel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | serious adverse events | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | cardiomyopathy (grade 3) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
First line therapy: 1 trials - Martin (motesanib)
| motesanib + paclitaxel vs paclitaxel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | serious adverse events | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | cardiomyopathy (grade 3) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Scagliottib MONET1
